Home › Agent Hub › Agent Tools › Part D coverage by drug › Glyxambi
Agent Tools
Glyxambi is a brand of empagliflozin / linagliptin. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 4,806 of 5,496 Medicare Part D and Medicare Advantage drug plans (87.4%) list Glyxambi on their formulary, across 298 of 328 formularies. The most common placement is tier 3 (4,423 plans, 92% of those covering it). 7 of the covering plans require prior authorization (0.1%), 0 step therapy and 4,653 a quantity limit.
1,298 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $47, 111 of them $0; 3,508 charge coinsurance instead — median 24% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 5,404 of 5,631 plans covered it (96%); 2026: 4,806 of 5,496 (87.4%).
Of 4,368 plans offered in both years, 21 added it to the formulary and 422 dropped it.
Among plans covering it both years, 285 moved it to a higher tier and 39 to a lower one; 5 added prior authorization and 0 removed it.
Medicare Part D paid for 243,834 30-day fills of Glyxambi in 2024 for about 28,712 enrollees, at an average total cost of $577.45 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Glyxambi and the rest of a client's list on every plan in their county.
Estimate Glyxambi costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.